AGP Executive Report
Last update: 10 hours agoBiotech Deal for Iceland Patients: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement worth up to €423.5m for senaparib, expanding access across EU states plus Iceland, Norway, Switzerland, the UK and parts of MENA—aimed at speeding availability after regulatory approvals. MS Treatment Pathway: Oculis reported positive U.S. FDA pre-IND feedback for Privosegtor in acute multiple sclerosis relapses, with an IND submission planned for Q4 2026. Chronic Liver Disease Hope: Researchers in Europe are pushing toward a “functional cure” for hepatitis B, noting millions in Iceland and across the region live with chronic infection despite vaccination. Genetics Behind Chronic Pain: A large Nature Medicine study identified 26 genome regions linked to fibromyalgia risk, supporting a biological basis tied to brain and nerve function. Solar Eclipse Safety (Iceland Included): Public health experts are urging safe viewing ahead of the Aug 12 solar eclipse, with totality expected in parts of Greenland and the western strip of Iceland (including Reykjavik). Health & Wellness Travel: Explora Journeys officially named its new LNG-powered ship, EXPLORA III, highlighting expanded wellness offerings—an “ocean state of mind” pitch for travellers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
